

Contents

Foreword	V
Preface	XXI
List of Contributors	XXIII

The History and Economic Relevance of Industrial Scale

Suspension Culture of Living Cells 1

Hans-Peter Meyer and Diego R. Schmidhalter

1	Introduction	2
2	A Short History of Suspension Culture (Fermentation)	2
2.1	Ethanol, Organic Acids, and Solvents, the Beginning	2
2.2	Vitamins Fermentation Takes a Long Time to Develop	4
2.3	Steroids, the First Large-Scale Biocatalysis Processes	5
2.4	Antibiotics, a US-Lead Turning Point in Fermentation Technology	5
2.5	Amino Acids, a Japanese Fermentation Success Story	8
2.6	Enzymes, a European Fermentation Success Story	9
2.7	Single Cell Proteins, an Economic Flop	9
2.8	Biofuels are Controversial Story	10
2.9	Recombinant DNA Technology Based Products (Monoclonal Antibodies and Other Recombinant Proteins), Setting off an Avalanche of New Products	11
3	The Contemporary Situation	11
3.1	How Long Can the USA Keep its Leading Role?	11
3.2	China and India Become Global Forces in Fermentation	12
4	The Future of Suspension Culture	13
4.1	New Frontiers	14
4.2	Yet “Uncultured” Cells and Organisms?	15
5	Economic and Market Considerations	16
5.1	The Pharmaceutical Market	19
5.2	Personal Care Products	25
5.3	Chemicals, Industrial and Technical Enzymes	27
5.4	Food, Dietary Supplements (Functional Food, Nutraceuticals), and Feed Products	27

6	Conclusions	32
	References	34

Part I Suspension Culture of Bacteria, Yeasts, and Filamentous Fungi 39

1	Bacterial Suspension Cultures	41
	<i>Patrick Sagmeister, Mohammadhadi Jazini, Joachim Klein, and Christoph Herwig</i>	
1.1	Introduction	41
1.2	Organisms, Cells, and their Products	42
1.2.1	Bacteria as Production Platform for Various Products	42
1.2.2	Historical Outline for <i>Escherichia coli</i>	44
1.2.3	Industrial Aspects of Bacterial Expression Systems	45
1.3	Bioprocess Design Aspects for Recombinant Products	51
1.3.1	Bacterial Cultivation Processes	51
1.3.2	Gram Negative Cell Factory: Cellular Compartments and Transport across Membranes	52
1.3.3	Industrial Strategies: Quality, Folding State, and Location of Recombinant Protein Products	53
1.3.4	Approaches towards Bioprocess Design, Optimization, and Manufacturing	55
1.3.5	Bacterial Bioprocess Design	56
1.3.5.1	Technical and Physiological Constraints for Bacterial Bioprocess Design	56
1.3.5.2	Media Design	57
1.3.5.3	Product Titer is Determined by the Biomass Concentration and the Specific Productivity q_p	58
1.3.6	Industrial Production Strategy by Two-Step Cultivation	59
1.3.6.1	Batch Phase for the Accumulation of Biomass	60
1.3.6.2	Structured Approach Towards Batch Design	60
1.3.6.3	Fed-Batch Phase Process Design from Scratch	61
1.3.6.4	Induction Phase: Product Formation Characteristics	63
1.3.6.5	Process Parameters Impacting Recombinant Product Formation	64
1.3.6.6	Concept of Time–Space Yield	65
1.4	Basic Bioreactor Design Aspects	66
1.4.1	Introduction	66
1.4.2	Vessel Design and Construction	67
1.4.3	Dimensioning	67
1.4.3.1	Materials of Construction	67
1.4.3.2	Surface Quality and Welding	69
1.4.3.3	Nozzles and Ports	70
1.4.4	Mass Transfer	70
1.4.5	Cleaning in Place	72
1.4.6	Steaming in Place	73

- 1.4.7 Monitoring and Control of Bioprocesses 73
- 1.4.7.1 Standard Instrumentation – Measuring and Control of Process Parameters 73
- 1.4.7.2 Challenges with Bioreactor Standard Sensors 74
- 1.4.7.3 Advanced Bioprocess Analytics: Real-Time Monitoring of Process Variables 74
- 1.5 Single Use Bioreactors for Microbial Cultivation 76
- 1.5.1 Multi-use or Single Use? 76
- 1.5.2 Challenges for the Use of Single Use Bioreactors in Microbial Bioprocesses 77
- 1.5.3 Microbial Bioprocess Development Using Single Use Bioreactors 77
- 1.5.4 Applications for Single Use Bioreactors in Microbial Suspension Cultures 79
- 1.6 Quality by Design: Vision or Threat for Twenty-First Century Pharmaceutical Manufacturing 79
- 1.6.1 Regulatory Drive towards the Implementation of QbD 80
- 1.6.2 Process Development along QbD Principles 82
- 1.6.3 Entry Points to QbD for Manufacturers 84
- 1.6.4 Challenges for Putting QbD Into Practice 84
- 1.6.5 Process Understanding for Biopharmaceutical Processes 85
- 1.6.5.1 Quality by Design – Opportunity or Threat for the Pharmaceutical Industry? 86
- 1.7 Process Economics 87
- 1.7.1 Optimization of Overall Productivity and Capital Expenses of the Production Facility 87
- 1.7.2 Further Economic Effects by Intracellular Product Location 88
- 1.7.3 Comparison of Product Yields, Intracellular Versus Extracellular 88
- References 90

2 Yeast Suspension Culture 95

Diethard Mattanovich, Carmen Jungo, Jana Wenger, Michal Dabros, and Michael Maurer

- 2.1 Introduction 95
- 2.2 Yeast Species Used in Biotechnology and their Products 96
- 2.2.1 Expression Systems 98
- 2.3 Basic Process Design Aspects 98
- 2.3.1 Process History 98
- 2.3.2 Yeast Fermentation Processes 99
- 2.3.3 Process Design for Ethanol Production 106
- 2.3.4 High Cell Density Fermentations – A Downstream Processing Challenge and a Yield Problem? 106
- 2.4 Basic Bioreactor Design Aspects 107
- 2.4.1 Bioreactors for Yeast Cultivation 107
- 2.4.2 Methanol, Safety and Explosion-Proof (Ex-proof) Measures 108
- 2.4.2.1 Concerns Regarding Methanol Use 108

2.4.2.2	Safety Issues and Equipment Design	108
2.4.2.3	Risk Assessment	109
2.4.2.4	Regulations	110
2.4.3	Process Monitoring and Control Solutions	111
2.4.3.1	The Classical Four	111
2.4.3.2	Advanced Bioprocess Monitoring and Control	112
2.5	Key Factors Related to Process Economics	114
2.5.1	Equipment Requirements	114
2.5.1.1	Upstream	114
2.5.1.2	Primary Recovery	114
2.5.1.3	Downstream Processing	115
2.5.2	Key Factors Related to Process Economics of the Fermentation Process	116
2.5.2.1	Raw Materials	116
2.5.2.2	Cycle Time	117
2.5.2.3	Formation of By-Products	118
2.5.3	Expression System and Its Impact on the Cost of Primary Recovery and Purification	118
2.5.4	Influence of the Expression System on the Analytical Scope in the Production	119
2.5.4.1	In-Process Controls (IPCs)	119
2.5.4.2	Final Release Analysis	119
2.5.4.3	Additional Costs	119
2.5.5	Estimation of Cost of Goods with Model Simulations	119
2.6	Regulatory Aspects	120
2.6.1	Food Ingredients	121
2.6.2	Pharmaceuticals	121
2.6.2.1	Regulatory Aspects to Consider/Guidelines	122
2.6.2.2	Construction and Quality of Cell Banks (Part of ICHQ5)	122
2.6.2.3	Manufacturing of APIs by Cell Culture or Microbial Fermentation (ICHQ7)	124
2.6.2.4	Test Procedures and Acceptance Criteria for Biotechnological Products (Part of ICHQ6)	125
2.6.2.5	Comparability of Biotechnological Products after Process Changes (Part of ICHQ5)	125
2.7	Summary and Outlook	126
	References	127
3	Filamentous Fungi Fermentation	131
	<i>Anders Nørregaard, Stuart M. Stocks, John M. Woodley, and Krist V. Gernaey</i>	
3.1	Introduction	131
3.2	Products and Organisms in the Industry	132
3.2.1	Background	132
3.2.2	Secondary Metabolites	133

3.2.3	Organic Acids	134
3.2.4	Proteins	134
3.3	Filamentous Fungi as a Production Platform	135
3.3.1	Expression Systems	135
3.3.2	Morphology	136
3.3.3	Genomic Tools	137
3.3.4	Sequencing and Genome Annotation	138
3.4	Fermentation of Filamentous Organisms	140
3.4.1	Fermentation Platforms	140
3.4.2	Reactor Design	141
3.4.3	Agitation and Aeration	141
3.4.4	Mass Transfer	143
3.4.5	Reactor Control	146
3.4.6	Rheology	147
3.4.7	Mixing Time and Cavern Formation	151
3.4.8	Correlation between Viscosity and k_{La}	151
3.5	Process Scaling	152
3.5.1	Dimensionless Numbers	153
3.5.2	Power Draw	154
3.5.3	Modeling Oxygen Mass Transfer	155
3.6	Regulatory Aspects	156
3.7	Economic Aspects	157
3.8	Conclusions and Perspectives	157
	References	158

Part II Suspension Culture of Algae and Plant Cells 163

4	Microalgae Grown under Heterotrophic and Mixotrophic Conditions	165
	<i>Karin Kovar, Pavel Přebyl, and Markus Wyss</i>	
4.1	Eco-physiology and Genetics of Biotechnologically Relevant Species	165
4.1.1	Taxonomy	166
4.1.2	Access to Axenic Cultures and Screening for Bioactivities	167
4.1.3	Biotechnologically Relevant Species and their Genetic Improvement	168
4.2	Products from Microalgae Grown in the Absence of Light	172
4.3	Bioreactor Design	174
4.4	Process Design: Culture Media and Process Control Strategies	174
4.5	Process Economics	176
4.6	Commercialization of Microalgae-Derived Products and Regulatory Aspects	176
	References	178

5	Recombinant Protein Production with Microalgae 187
	<i>Alexandre Lejeune, Rémy Michel, and Aude Carlier</i>
5.1	Organisms, Cells, Expression Systems, Products 187
5.2	Production of Recombinant Therapeutics in Microalgae: Process Design Aspects 189
5.2.1	Overall Process Overview: From Genetic Transformation to Cell Banking 189
5.2.2	Basic Aspects of Cultivation of Microalgal Cells for Production of Recombinant Therapeutic Proteins 190
5.3	Regulatory Aspects 192
5.4	Summary and Outlook 194
	References 195
6	Suspension Culture of Microorganisms (Algae and Cyanobacteria) Under Phototrophic Conditions 199
	<i>Peter Bergmann, Astrid Nissen, Lars Beyer, Peter Ripplinger, and Walter Trösch</i>
6.1	Introduction 199
6.1.1	Photosynthetic Microorganisms (Algae and Cyanobacteria) in General 200
6.1.2	Microalgal Evolution and Taxonomy 201
6.1.3	Microalgae in Biotechnology 201
6.1.4	Industrial Microalgae Biotechnology – A Brief History 202
6.2	Basic Process Design Aspects 203
6.3	Large-Scale Cultivation Systems 206
6.3.1	Open Ponds – Technology Overview 207
6.3.2	Open Ponds – Production Sites 208
6.3.3	Open Ponds – Performance 209
6.3.4	Open Ponds – Energy Consumption 210
6.4	Photobioreactors – Technology Overview 211
6.4.1	Photobioreactors – Tubular 212
6.4.1.1	Tubular Photobioreactors – Production Sites 213
6.4.1.2	Tubular Photobioreactors – Performance 213
6.4.1.3	Tubular Photobioreactors – Energy Consumption 214
6.4.2	Photobioreactors – Flat-Plate 215
6.4.2.1	Flat-Plate Photobioreactors – Production Sites 217
6.4.2.2	Flat-Plate Photobioreactors – Performance 217
6.4.2.3	Flat-Plate Photobioreactors – Energy Consumption 217
6.5	Conclusion/Outlook 218
	References 219
7	Suspension Culture of Plant Cells Under Heterotrophic Conditions 225
	<i>Nicole Imseng, Stefan Schillberg, Cornelia Schürch, Daniel Schmid, Kai Schütte, Gilbert Gorr, Dieter Eibl, and Regine Eibl</i>
7.1	Introduction 225

7.2	<i>In Vitro</i> Initiation and Maintenance of Plant Cell Suspension Cultures	229
7.2.1	General Procedure	229
7.2.2	Plant Stem Cells	231
7.2.3	Non-transformed and Genetically Modified Plant Cell Suspensions	233
7.3	Characteristics of Heterotrophic Plant Suspension Cells and Resulting Process Design	235
7.3.1	Culture Characteristics and Typical Cultivation Parameters	235
7.3.2	Primary Cell Metabolism and Culture Media	236
7.3.3	Process Mode	237
7.4	Suitable Bioreactors	238
7.4.1	Categorization Approach	238
7.4.2	Most Often Used Bioreactors Types	240
7.5	Commercial Manufacture of Plant Cell-Derived Cosmetics and Therapeutics under Additional Consideration of Economic and Regulatory Aspects	243
7.5.1	Case Study: PhytoCellTec™ <i>Malus domestica</i>	243
7.5.1.1	Production Process	243
7.5.1.2	Effectiveness of the Bioactive Ingredients Produced <i>In Vitro</i>	244
7.5.2	Case Study: Paclitaxel	248
7.5.2.1	Introduction	248
7.5.2.2	Cell Line Development and Cryopreservation	249
7.5.2.3	PCF™ Process Conditions	250
7.5.2.4	Summary	252
7.6	Conclusion	252
	References	252
8	Suspension Culture of Plant Cells Under Phototrophic Conditions	261
	<i>Holger Niederkrüger, Paulina Dabrowska-Schlepp, and Andreas Schaaf</i>	
8.1	Introduction	261
8.2	BryoTechnology™: Production of Biologics with Moss (<i>Physcomitrella patens</i>)	262
8.2.1	Characteristics of BryoTechnology™	262
8.2.1.1	Moss Taxonomy and Natural Habitats	262
8.2.1.2	Life Cycle and Physiology	262
8.2.1.3	Homologous Recombination	263
8.2.1.4	Recombinant Protein Production	265
8.2.2	Basic Process Design Aspects	265
8.2.2.1	Transformation	265
8.2.2.2	Expression Vectors	266
8.2.2.3	Strain Development	266
8.2.2.4	Cell Banking	267
8.2.2.5	Upstream Process	267
8.2.2.6	Harvest	269

8.2.2.7	Downstream	271
8.2.2.8	Timelines of Process Development	272
8.2.3	Basic Bioreactor Design Aspects	272
8.2.3.1	Illumination	275
8.2.3.2	Biomass Handling	275
8.2.3.3	IPC	276
8.2.3.4	Process Scale-Up	276
8.2.3.5	Current Limitations	277
8.2.4	Summary and Outlook	279
8.3	The LEX-System: Production of Biologics with Duckweed (<i>Lemna minor</i>)	280
8.3.1	Characteristics of the LEX-System	280
8.3.1.1	Duckweed Taxonomy, Physiology and Morphology	280
8.3.1.2	Biotechnological Aspects of Duckweed	280
8.3.1.3	Timelines of Process Development	281
8.3.2	Basic Process Design Aspects	281
8.3.2.1	Expression Vectors	281
8.3.2.2	Strain Development	282
8.3.2.3	Master-Plant Banking	282
8.3.2.4	Upstream Process	282
8.3.2.5	Downstream	283
8.3.3	Basic Bioreactor Design Aspects	284
8.3.4	Summary and Outlook	285
8.4	Key Factors Related to Process Economics	285
8.5	Regulatory Aspects	286
	References	288

Part III Suspension Culture of Protozoa, Insect Cells, Avian Cells, and Mammalian Cells 293

9	Suspension Culture of Protozoan Organisms	295
	<i>Marcus W.W. Hartmann and Reinhard Breitling</i>	
9.1	Introduction	295
9.2	Ciliates	296
9.2.1	Specific Features of Ciliates	296
9.2.2	Suspension Culture of Ciliates	299
9.2.3	Strengths of the Ciliate <i>Tetrahymena thermophila</i>	304
9.2.3.1	Mass Cultivation, Scalability, and Usability of Market Standard Fermentation Equipment	304
9.2.3.2	Reliable High-Efficiency Transformation Protocols	305
9.2.3.3	Established Expression Vectors	305
9.2.3.4	Serum-Free Complex- and Chemically-Defined Media	307
9.2.3.5	Consistent and Advantageous N-Glycosylation with Lack of Fucose	309

9.2.4	Challenges for using <i>Tetrahymena</i> in Production of Recombinant Proteins	310
9.2.4.1	Lack of Terminal Sialylation and γ -Carboxylation as Post-translational Modifications	310
9.2.5	Big Lines to Classes of Products and Main Markets	311
9.2.5.1	<i>Tetrahymena</i> as New Production Platform Technology	311
9.2.6	Basic Process Design Aspects for <i>Tetrahymena</i> Suspension Culture	313
9.2.6.1	Principal Bioreactor Set Up for <i>Tetrahymena</i> Suspension Culture	313
9.2.6.2	Inoculation Titer, Cell Counting and Dry Mass	314
9.2.6.3	Agitation Rate and Shear Stress	315
9.2.6.4	Aeration, Dissolved Oxygen Concentration, and Antifoam Reagents	315
9.2.6.5	Mucocyst Material	316
9.2.7	Basic Bioreactor Design Aspects for <i>Tetrahymena</i> Suspension Culture	316
9.2.8	Key Factors in Process Economics	317
9.2.8.1	Investment Costs	317
9.2.8.2	Cost of Goods for Fermentation	318
9.2.8.3	Other Costs	318
9.3	Flagellates	319
9.3.1	Specific Features of Flagellates	319
9.3.2	Suspension Culture of Hemoflagellates	322
9.3.3	Strengths of the Hemoflagellate <i>Leishmania tarentolae</i>	324
9.3.4	Challenges for the Application of the Hemoflagellate <i>Leishmania tarentolae</i>	326
9.3.5	Big Lines to Classes of Products and Main Markets	327
9.3.6	Basic Process Design Aspects for <i>Leishmania</i> Suspension Culture	328
9.3.7	Basic Bioreactor Design Aspects for <i>Leishmania</i> Suspension Culture	331
9.3.8	Key Factors for Process Economics	332
9.4	Regulatory Aspects of Protozoan Production Organism	334
9.5	Summary and Outlook	335
	References	336
10	Industrial Large Scale of Suspension Culture of Insect Cells	349
	<i>Antônio Roldão, Manon Cox, Paula Alves, Manuel Carrondo, and Tiago Vicente</i>	
10.1	History	349
10.2	Concepts in Insect Cell Culture	351
10.2.1	Cell Types, Expression Systems, and Products	351
10.2.2	Maintaining Insect Cells in Culture – Requirements of the Bioreactor Design	358
10.2.3	Insect Cell Metabolism: A Brief Overview	364
10.2.4	A Bottom-Up Approach for Industrial Insect Cell-Based Cultures	366
10.2.4.1	Upstream Process Development Strategies	367

- 10.2.4.2 Downstream Process Development Strategies 370
- 10.3 Regulatory Hurdles for Insect Derived Human Products 374
- 10.3.1 Case Study: Flublok[®] Regulatory History 376
- 10.4 What Comes Next? 377
- 10.4.1 Improvements in Production Cycle and Yields 377
- References 378

11 Avian Suspension Culture Cell Lines for Production of Vaccines and Other Biologicals 391

Manfred Reiter, Daniel Portsmouth, and P. Noel Barrett

- 11.1 Development of Cell Culture for the Production of Vaccines and Biologicals 391
- 11.2 Avian Cell Lines 393
- 11.3 Potential of Avian Cell Lines for the Manufacture of Vaccines and Biologicals 394
 - 11.3.1 Modified Vaccinia Virus Ankara (MVA) Vaccines 394
 - 11.3.2 Yellow Fever Vaccines 394
 - 11.3.3 TBEV Vaccines 395
 - 11.3.4 Influenza Vaccines 395
 - 11.3.5 Monoclonal Antibodies 397
- 11.4 Development of Avian Cell Lines 397
 - 11.4.1 EB66 (Vivalis) 398
 - 11.4.2 AGE1.CR (Probiogen) 399
 - 11.4.3 QOR2/2E11 (Baxter) 400
 - 11.4.3.1 Establishment of QOR2/2E11 400
 - 11.4.3.2 Characterization and GMP Qualification 401
 - 11.4.3.3 Virus growth in QOR2/2E11 Cells 401
 - 11.4.3.4 MVA Virus Replication on QOR2/2E11 Cells at Different MOIs and Temperature 403
 - 11.4.4 Chicken Embryo Cell Line PBS-12SF (Michigan State University, USA) 405
- 11.5 Basic Process Design Aspects 405
- 11.6 Basic Bioreactor Design Aspects 405
- 11.7 Key Factors Related to Process Economics 405
- 11.8 Regulatory Aspects 406
- 11.9 Summary and Outlook 406
- References 407

12 Large Scale Suspension Culture of Mammalian Cells 411

Richard M. Allread, John R. Birch, Hilary K. Metcalfe, Suzanne Farid, Andrew J. Racher, Robert J. Young, and Mohsan Khan

- 12.1 Introduction to Mammalian Cell Culture 412
 - 12.1.1 Brief History of the Use of Mammalian Cell Culture 412
 - 12.1.2 Why Mammalian Cells for Protein Production? 413
 - 12.1.3 Commercial Importance of Mammalian Cell Culture 414

12.1.4	Mammalian Cell Culture Industry	415
12.2	Cell Lines and Expression Technologies	417
12.2.1	Introduction	417
12.2.2	Host Cell Lines for Manufacturing Therapeutic Proteins	419
12.2.2.1	Regulatory Acceptance	419
12.2.2.2	Productivity of CHO Cell Lines	419
12.2.2.3	Cell Line Development Timeline	420
12.2.2.4	Product Characteristics	420
12.2.2.5	Current Status and Future Developments	420
12.2.3	Selecting Highly Productive Cell Lines	421
12.2.4	Expression Vector Architecture	421
12.2.4.1	Insulator and Chromatin Opening Sequences	423
12.2.5	Selection Markers	424
12.2.6	Targeted Integration	425
12.3	Bioreactor Design	427
12.3.1	Introduction	427
12.3.2	Types of Mammalian Cell Culture Bioreactors	428
12.3.2.1	Stirred-Tank Bioreactor	428
12.3.2.2	Airlift Bioreactor	429
12.3.2.3	Wave-Based Bioreactor	430
12.3.3	Scale Up Considerations	431
12.3.3.1	Mixing	431
12.3.3.2	Mass Transfer	432
12.3.3.3	Shear	432
12.3.3.4	Pressure	432
12.3.3.5	Scale up Strategy	433
12.3.4	Sterilization and Cleaning	433
12.3.5	Single Use Bioreactor Systems	435
12.4	Process Operation	436
12.4.1	Batch and Fed-Batch Culture	436
12.4.2	Perfusion Culture	438
12.4.3	Culture Media and Feeds	439
12.4.4	Non-nutrient Additions	439
12.4.5	Control Parameters	440
12.4.5.1	Temperature	440
12.4.5.2	pH	441
12.4.5.3	Dissolved Oxygen Concentration	442
12.4.5.4	Carbon Dioxide Concentration	442
12.4.5.5	Osmolarity	443
12.5	Process Economics of Mammalian Cell Culture	443
12.5.1	Process Economic Challenges	443
12.5.2	Process Economic Drivers	444
12.5.3	Antibody Process Economics Case Studies	447
12.5.3.1	Stainless Steel versus Single Use Decisions	447
12.5.3.2	Fed-Batch versus Perfusion Decisions	448

- 12.5.3.3 Robustness of Legacy Purification Facilities to Higher Titer Processes 450
- 12.6 Regulatory Aspects 450
- 12.6.1 Source, History, and Generation of the Cell Substrate 451
- 12.6.2 Cell Banks 452
- 12.6.3 Cell Substrate Stability 452
- 12.6.4 Expression Vector 452
- 12.6.5 Characterization of Cell Banks 452
- 12.6.6 Quality by Design (QbD) 453
- 12.7 Summary and Outlook 453
- References 455

Part IV Suspension Culture for Special Products 463

13 Pillars of Regenerative Medicine: Therapeutic Human Cells and Their Manufacture 465

Christian van den Bos, Robert Keefe, Carmen Schirmaier, and Michael McCaman

- 13.1 Introduction 465
- 13.1.1 Regeneration 465
- 13.1.2 Therapeutically Valuable Cells 466
- 13.2 Autologous Therapies 468
- 13.2.1 T-Cells 470
- 13.2.2 Dendritic Cells 473
- 13.2.3 Natural Killer Cells 474
- 13.2.4 Hematopoietic Stem Cells 475
- 13.3 Allogeneic Therapies 476
- 13.3.1 Background 476
- 13.3.2 Current Definition 477
- 13.3.3 Activity 477
- 13.3.4 Animal Models 478
- 13.3.5 Safety 479
- 13.3.6 Lack of Rejection 479
- 13.3.7 Immunity and Manufacturing 480
- 13.3.8 Manufacturing and Technology Transitions 480
- 13.3.9 Challenges to Manufacturing 480
- 13.3.9.1 Dosing 481
- 13.3.9.2 Biological Limitations to Culture Expansion Yields 482
- 13.3.9.3 Regulatory Expectations 482
- 13.3.10 Markers versus Process 483
- 13.3.11 Current Solutions 483
- 13.3.12 Forthcoming Solutions, Lessons from Bioproduction versus MSC Biology 484

- 13.3.13 Adaptation/Directed Evolution of Industrial Cell Lines 486
- 13.3.14 Therapeutic Cells Should not be Adapted 486
- 13.3.15 Providing Scalable Adhesion Surfaces in Stirred-Tank Bioreactors: Microcarrier Based Bioreactor Processes 487
- 13.3.15.1 Expanding Adult Somatic Stem Cells: A Medium Scale Bioreactor Example 488
- 13.3.16 Critical Quality Attributes (CQAs) for Therapeutic Cells 488
- 13.3.17 Potency 490
- 13.3.18 Practical Challenges 493
- 13.3.19 Future Directions for Cell Testing 493
- 13.4 Downstream Processing 494
- 13.5 Key Factors Towards Economic Success 496
- 13.6 Regulatory Considerations 497
- 13.7 Summary and Outlook 497
- References 498

- 14 Virus Production Under Suspension Conditions 503**
Otto-Wilhelm Merten, Wilfried A.M. Bakker, Jürgen Vorlop, Manfred Reiter, Gabriel Visnovsky, Volker Jäger, Maia Merabishvili, and Udo Reichl
- 14.1 Introduction 503
- 14.2 Adherent versus Suspension Culture for Virus Production 504
- 14.2.1 Viral Vaccines for Human use Produced with Microcarrier Based Manufacturing Processes 506
- 14.2.2 Towards Single Cell Suspension Processes for Virus Production 506
- 14.3 Polio Virus/Vaccines 508
- 14.3.1 Introduction 508
- 14.3.2 Large-Scale IPV Manufacturing Using Vero Cells Grown on Microcarriers 509
- 14.3.3 Per.C6 and Other Cell Lines for Future Polio Vaccine Production 509
- 14.3.4 Future Perspectives in IPV Manufacturing 511
- 14.4 Influenza Virus/Vaccines 512
- 14.4.1 Introduction 512
- 14.4.2 Use of Anchorage Dependent Cell Lines – Development of Microcarrier Based Suspension Processes 512
- 14.4.3 Use of Cell Lines Adapted to Suspension Growth 514
- 14.5 Modified Vaccinia Ankara (MVA) Production in Suspension Cell Lines 517
- 14.6 Production of Viruses for Gene Therapy Purpose 519
- 14.6.1 Large Scale Adenovirus Production Using Suspension Culture Processes 520
- 14.6.2 Large Scale AAV Production Using Suspension Culture Processes – Comparison of Different Production Systems 523
- 14.6.3 LV Vector Production – Towards the Use of Suspension Process for Transient Vector Production 527

14.7	Other Viruses	532
14.7.1	Production of Viruses for Veterinary Vaccines	532
14.7.2	Production of Bio-pesticides using the Insect Cell/Baculovirus System	533
14.7.3	Production of Bacteriophages Using Bacterial Suspension Cultures for Phage-Therapy	537
14.7.3.1	Introduction	537
14.7.3.2	Bacterial Strains – Selection for Bacteriophage Generation	538
14.7.3.3	Bacteriophages – Isolation	539
14.7.3.4	Bacteriophages – Production	540
14.7.3.5	Large Scale Production of Phages	540
14.8	Concluding Remarks	542
	References	543

15 Cultivable Marine Organisms as a Source of New Products 555

Jean-Michel Kornprobst

15.1	Introduction	555
15.2	Substances of Interest Isolated from Archaea and Prokaryotes	557
15.2.1	Archaea	557
15.2.2	Non-photosynthetic Bacteria	558
15.2.3	Cyanobacteria	560
15.3	Substances of Interest Isolated from Unicellular Eukaryotes	560
15.3.1	Unicellular Chlorophyta and Rhodophyta	563
15.3.2	Diatoms, Chrysophyceae, Raphidophyceae, and Eustigmatophyceae	564
15.3.3	Haptophyceae (= Prymnesiophyceae)	565
15.3.4	Fungi and Thraustochytrids	565
15.3.5	Dinoflagellates	567
15.4	Substances of Interest Isolated from Microorganisms Associated with Pluricellular Organisms	570
15.4.1	Bacteria and Sponges	570
15.4.2	Bacteria and Bryozoans	572
15.4.3	Bacteria, Prochlorophyta, and Didemnidae	572
15.4.4	Dinoflagellates and Cnidaria	573
15.4.5	Dinoflagellates and Platyhelminthes (Flat Worms)	575
15.5	Substances of Interest Produced by Sponge Cell Culture	575
15.6	Substances of Interest Isolated by Culture of Macroorganisms	575
15.6.1	Red Algae and Marine Spermatophyta	578
15.6.2	Green algae and Molluscs	579
15.7	Conclusion and Future Prospects	579
	References	584

Index 593